Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiad293 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Sunwen Chou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Dichlororibofuranosylbenzimidazole, Ribonucleosides. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
This drug resistance analysis of a randomized trial includes 234 patients receiving maribavir and 116 receiving investigator-assigned standard therapy (IAT), where 56% and 24%, respectively, cleared cytomegalovirus DNA at week 8 (treatment responders).
Methods
Baseline and posttreatment plasma samples were tested for mutations conferring drug resistance in viral genes UL97, UL54, and UL27.
Results
At baseline, genotypic testing revealed resistance to ganciclovir, foscarnet, or cidofovir in 56% of patients receiving maribavir and 68% receiving IAT, including 9 newly phenotyped mutations. Among them, 63% (maribavir) and 21% (IAT) were treatment responders. Detected baseline maribavir resistance mutations were UL27 L193F (n = 1) and UL97 F342Y (n = 3). Posttreatment, emergent maribavir resistance mutations were detected in 60 (26%) of those randomized to maribavir, including 49 (48%) of 103 nonresponders and 25 (86%) of the 29 nonresponders where viral DNA initially cleared then rebounded while on maribavir. The most common maribavir resistance mutations were UL97 T409M (n = 34), H411Y (n = 26), and C480F (n = 21), first detected 26 to 130 (median 56) days after starting maribavir.
Conclusions
Baseline maribavir resistance was rare. Drug resistance to standard cytomegalovirus antivirals did not preclude treatment response to maribavir. Rebound in plasma cytomegalovirus DNA while on maribavir strongly suggests emerging drug resistance. Clinical Trials Registration NCT02931539.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA.
- Research and Development Service, Veterans Affairs Portland Health Care System, Portland, Oregon, USA.
- Department of Virology and National Reference Center for Herpesviruses, Limoges University Hospital, UMR Inserm 1092, University of Limoges, Limoges, France.
- Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
- Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Sophie Alain, Jens Lundgren
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- NIH HHS
- Takeda Development Center Americas, Inc
- National Institutes of Health
- US Department of Veterans Affairs
Zitieren
APA
Chou, S., Alain, S., Cervera, C., Chemaly, R. F., Kotton, C. N., Lundgren, J., Papanicolaou, G. A., Pereira, M. R., Wu, J. J., Murray, R. A., Buss, N. E., & Fournier, M. (2024). Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad293
Vancouver
Chou S, Alain S, Cervera C, Chemaly RF, Kotton CN, Lundgren J, et al. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad293
BibTeX
@article{Chou2024,
author = {Chou, Sunwen and Alain, Sophie and Cervera, Carlos and Chemaly, Roy F and Kotton, Camille N and Lundgren, Jens and Papanicolaou, Genovefa A and Pereira, Marcus R and Wu, Jingyang J and Murray, Rose Ann and Buss, Neil E and Fournier, Martha},
title = {Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiad293}
}
EUVIMED